PMID- 9412543
OWN - NLM
STAT- MEDLINE
DCOM- 19980120
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 80
IP  - 11A
DP  - 1997 Dec 4
TI  - Effects of beta blockers on symptoms and functional capacity in heart failure.
PG  - 55L-58L
AB  - Beta-adrenergic-blocking drugs ameliorate the progression of disease that usually 
      characterizes heart failure. All of the larger multicenter studies have 
      demonstrated reductions in morbidity, manifested by a reduction in the number of 
      hospitalizations and/or listing for cardiac transplantation, whereas studies with 
      carvedilol have also reported a significant reduction in mortality. The influence 
      of beta-adrenergic blocking drugs on the symptomatic and functional status of 
      patients with heart failure has been more difficult to establish. Almost all 
      trials have reported an improvement in New York Heart Association (NYHA) 
      functional class, with few patients experiencing functional deterioration. 
      Improvement in symptom score was reported in the Metoprolol in Dilated 
      Cardiomyopathy (MDC) trial far patients treated with metoprolol. In patients from 
      the US Carvedilol Heart Failure Trials Program who had heart failure from 
      ischemic and nonischemic etiologies, both patients and physicians reported more 
      improvement and less deterioration in an assessment of global status. More formal 
      instruments to assess quality of life, such as the specific activity scale in the 
      Australia-New Zealand trial of carvedilol (that recruited 30% of patients who bad 
      improved to NYHA stage I) and the Minnesota Quality of Life questionnaire, did 
      not seem sensitive to the clinical benefits observed in these trials. Serial 
      exercise testing similarly does not seem sensitive to the beneficial influence of 
      beta-adrenergic blocking drugs on disease progression, at least in relatively 
      short-term studies.
FAU - Fowler, M B
AU  - Fowler MB
AD  - Division of Cardiovascular Medicine, Stanford University Medical Center, 
      California 94305, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/pharmacology/*therapeutic use
MH  - Carbazoles/therapeutic use
MH  - Carvedilol
MH  - Exercise Tolerance/drug effects
MH  - Heart Failure/classification/*drug therapy/physiopathology
MH  - Hospitalization
MH  - Humans
MH  - Metoprolol/therapeutic use
MH  - Morbidity
MH  - Propanolamines/therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 1997/12/31 00:00
MHDA- 1997/12/31 00:01
CRDT- 1997/12/31 00:00
PHST- 1997/12/31 00:00 [pubmed]
PHST- 1997/12/31 00:01 [medline]
PHST- 1997/12/31 00:00 [entrez]
AID - S0002-9149(97)00849-7 [pii]
AID - 10.1016/s0002-9149(97)00849-7 [doi]
PST - ppublish
SO  - Am J Cardiol. 1997 Dec 4;80(11A):55L-58L. doi: 10.1016/s0002-9149(97)00849-7.